|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM37293465X |
| 003 |
DE-627 |
| 005 |
20250306061521.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240528s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202310731
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1242.xml
|
| 035 |
|
|
|a (DE-627)NLM37293465X
|
| 035 |
|
|
|a (NLM)38805174
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kong, Ying
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Ultrasmall Polyphenol-NAD+ Nanoparticle-Mediated Renal Delivery for Mitochondrial Repair and Anti-Inflammatory Treatment of AKI-to-CKD Progression
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.07.2024
|
| 500 |
|
|
|a Date Revised 25.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a As a central metabolic molecule, nicotinamide adenine dinucleotide (NAD+) can potentially treat acute kidney injury (AKI) and chronic kidney disease (CKD); however, its bioavailability is poor due to short half-life, instability, the deficiency of targeting, and difficulties in transmembrane transport. Here a physiologically adaptive gallic acid-NAD+ nanoparticle is designed, which has ultrasmall size and pH-responsiveness, passes through the glomerular filtration membrane to reach injured renal tubules, and efficiently delivers NAD+ into the kidneys. With an effective accumulation in the kidneys, it restores renal function, immune microenvironment homeostasis, and mitochondrial homeostasis of AKI mice via the NAD+-Sirtuin-1 axis, and exerts strong antifibrotic effects on the AKI-to-CKD transition by inhibiting TGF-β signaling. It also exhibits excellent stability, biodegradable, and biocompatible properties, ensuring its long-term safety, practicality, and clinical translational feasibility. The present study shows a potential modality of mitochondrial repair and immunomodulation through nanoagents for the efficient and safe treatment of AKI and CKD
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a acute kidney injury
|
| 650 |
|
4 |
|a chronic kidney disease
|
| 650 |
|
4 |
|a inflammation
|
| 650 |
|
4 |
|a mitochondria
|
| 650 |
|
4 |
|a nanoparticle
|
| 650 |
|
4 |
|a nicotinamide adenine dinucleotide
|
| 650 |
|
7 |
|a NAD
|2 NLM
|
| 650 |
|
7 |
|a 0U46U6E8UK
|2 NLM
|
| 650 |
|
7 |
|a Polyphenols
|2 NLM
|
| 650 |
|
7 |
|a Anti-Inflammatory Agents
|2 NLM
|
| 650 |
|
7 |
|a Gallic Acid
|2 NLM
|
| 650 |
|
7 |
|a 632XD903SP
|2 NLM
|
| 700 |
1 |
|
|a Chen, Xu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Feng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tang, Jiageng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Yijing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Xiangxiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Luyao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Tong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Yaqi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Su, Mengxiao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Qixin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Hanxiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Di
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yi, Fan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Hong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fu, Yi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 30 vom: 31. Juli, Seite e2310731
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:30
|g day:31
|g month:07
|g pages:e2310731
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202310731
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 30
|b 31
|c 07
|h e2310731
|